Prima BioMed Receives A $1.3 Million Tax Refund From French Government
16 Août 2017 - 4:01AM
Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the
“Company”) is pleased to announce that it has received a €876,635
(A$1,306,266) cash rebate from the French Government under its
Crédit d’Impôt Recherche scheme (CIR). Through CIR the French
government reimburses companies, whether French or international,
for undertaking research and development activity in France by up
to 30%.
Prima BioMed qualifies to receive CIR credits via
its subsidiary Immutep due to R&D conducted in its laboratory
at Châtenay-Malabry in southwestern Paris in the 2016 calendar
year. Prima is currently working on new products in addition to the
development work related to lead compound IMP321, in both cancer
treatment and other settings.
The additional funding will be used for the
development of its IMP321 clinical trial programs in Europe and
Australia.
About Prima BioMed
Prima BioMed is listed on the Australian
Securities Exchange and on the NASDAQ in the US. For further
information please visit www.primabiomed.com.au.
For further information please contact:
U.S. Investors:
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com
Immutep Limited (NASDAQ:PBMD)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Immutep Limited (NASDAQ:PBMD)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024
Real-Time news about Immutep Limited (NASDAQ): 0 recent articles
Plus d'articles sur